bioMD Limited, a publicly listed company, is involved in the global marketing of the ADAPT® Advanced Tissue Process technology. This process has been developed over a period of 7 years and is used in the treatment of animal tissues for use as bioimplants in humans. The ADAPT® process produces a more durable implant by reducing calcification to less than normal physiological levels, reducing the immune response to zero and providing a regenerative biocompatible implant. This technology has produced outstanding results in pre-clinical in vivo animal studies. Indications for use include repair of congenital heart deformities, vascular aortic valve conduits and other applications in the more general areas of pelvic floor repair and orthopaedic reconstructions. The process can be used with any collagen based tissue, and its enhanced crosslinking and effective anti-calcification produces a bioimplant with advanced in vivo capabilities.